386 related articles for article (PubMed ID: 34376534)
1. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
Casarrubios M; Cruz-Bermúdez A; Nadal E; Insa A; García Campelo MDR; Lázaro M; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; de Castro-Carpeño J; Cobo M; López-Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Massuti B; Barquín M; Laza-Briviesca R; Sierra-Rodero B; Parra ER; Sanchez-Espiridion B; Rocha P; Kadara H; Wistuba II; Romero A; Calvo V; Provencio M
Clin Cancer Res; 2021 Nov; 27(21):5878-5890. PubMed ID: 34376534
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
[TBL] [Abstract][Full Text] [Related]
3. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
Laza-Briviesca R; Cruz-Bermúdez A; Nadal E; Insa A; García-Campelo MDR; Huidobro G; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Massuti B; Casarrubios M; Sierra-Rodero B; Tarín C; García-Grande A; Haymaker C; Wistuba II; Romero A; Franco F; Provencio M
Clin Transl Med; 2021 Jul; 11(7):e491. PubMed ID: 34323406
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.
Zhang J; Ji Z; Caushi JX; El Asmar M; Anagnostou V; Cottrell TR; Chan HY; Suri P; Guo H; Merghoub T; Chaft JE; Reuss JE; Tam AJ; Blosser RL; Abu-Akeel M; Sidhom JW; Zhao N; Ha JS; Jones DR; Marrone KA; Naidoo J; Gabrielson E; Taube JM; Velculescu VE; Brahmer JR; Housseau F; Hellmann MD; Forde PM; Pardoll DM; Ji H; Smith KN
Clin Cancer Res; 2020 Mar; 26(6):1327-1337. PubMed ID: 31754049
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.
Sierra-Rodero B; Cruz-Bermúdez A; Nadal E; Garitaonaindía Y; Insa A; Mosquera J; Casal-Rubio J; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Massuti B; Laza-Briviesca R; Casarrubios M; García-Grande A; Romero A; Franco F; Provencio M
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446577
[TBL] [Abstract][Full Text] [Related]
7. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
Rocha P; Zhang J; Laza-Briviesca R; Cruz-Bermúdez A; Bota-Rabassedas N; Sanchez-Espiridon B; Yoshimura K; Behrens C; Lu W; Tang X; Pataer A; Parra ER; Haymaker C; Fujimoto J; Swisher SG; Heymach JV; Gibbons DL; Lee JJ; Sepesi B; Cascone T; Solis LM; Provencio M; Wistuba II; Kadara H
Clin Cancer Res; 2022 Jun; 28(11):2461-2473. PubMed ID: 35394499
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.
Deng H; Zhao Y; Cai X; Chen H; Cheng B; Zhong R; Li F; Xiong S; Li J; Liu J; He J; Liang W
Crit Rev Oncol Hematol; 2022 Feb; 170():103582. PubMed ID: 35031441
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
[TBL] [Abstract][Full Text] [Related]
10. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
[TBL] [Abstract][Full Text] [Related]
11. T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.
Wu L; Zhu J; Rudqvist NP; Welsh J; Lee P; Liao Z; Xu T; Jiang M; Zhu X; Pan X; Li P; Zhou Z; He X; Yin R; Feng J
Front Immunol; 2021; 12():719285. PubMed ID: 34733273
[TBL] [Abstract][Full Text] [Related]
12. Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers.
Han J; Yu R; Duan J; Li J; Zhao W; Feng G; Bai H; Wang Y; Zhang X; Wan R; Xu J; Wang X; Guan Y; Xia X; Yao Z; Fei K; Carbone DP; Wang Z; Wang J
Sci Adv; 2021 May; 7(21):. PubMed ID: 34138742
[TBL] [Abstract][Full Text] [Related]
13. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
[TBL] [Abstract][Full Text] [Related]
15. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
16. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
17. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
18. Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.
Naidus E; Bouquet J; Oh DY; Looney TJ; Yang H; Fong L; Standifer NE; Zhang L
Cancer Immunol Immunother; 2021 Jul; 70(7):2095-2102. PubMed ID: 33420629
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Forde PM; Chaft JE; Smith KN; Anagnostou V; Cottrell TR; Hellmann MD; Zahurak M; Yang SC; Jones DR; Broderick S; Battafarano RJ; Velez MJ; Rekhtman N; Olah Z; Naidoo J; Marrone KA; Verde F; Guo H; Zhang J; Caushi JX; Chan HY; Sidhom JW; Scharpf RB; White J; Gabrielson E; Wang H; Rosner GL; Rusch V; Wolchok JD; Merghoub T; Taube JM; Velculescu VE; Topalian SL; Brahmer JR; Pardoll DM
N Engl J Med; 2018 May; 378(21):1976-1986. PubMed ID: 29658848
[TBL] [Abstract][Full Text] [Related]
20. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]